Every material Form 8-K Cytosorbents Corp has filed with the SEC since August 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
CytoSorbents said it regained compliance with Nasdaq's $1.00 minimum bid price requirement after its closing bid price was at or above $1.00 for 10 consecutive trading sessions ending September 21, 2026, and Nasdaq closed that matter on September 22, 2026. The company still has not met Nasdaq's $35 million minimum market value of listed securities requirement, which it must meet by December 28, 2026, or it will receive a delisting notice, and the company states there is no assurance it will maintain its Nasdaq listing.
Nasdaq notified the company on September 22, 2026 that it regained compliance with the $1.00 minimum bid price requirement and closed the matter.
The company must have listed securities worth at least $35 million for 10 consecutive business days by December 28, 2026 to regain compliance with the market value requirement.
The company is evaluating actions and may consider increasing stockholders' equity to at least $2.5 million.
If the company does not regain compliance by December 28, 2026, it will receive a delisting notice and may appeal.
CytoSorbents furnished an investor presentation for its Q2 2026 earnings call held August 6, 2026. Product revenue was flat year over year at $9.6 million, while gross margin rose to 73% from 71% and the operating loss narrowed to $2.6 million from $3.6 million. The company continues to expect operating cash flow breakeven in the second half of 2026.
Q2 2026 product revenue was $9.6 million, unchanged from the prior year; Germany sales fell 24% to $2.5 million.
Gross margin rose to 73% from 71%, and total operating expenses fell to $9.7 million from $10.4 million.
Adjusted net loss narrowed 22% to $2.9 million ($0.05 per share) and adjusted EBITDA loss narrowed 38% to $1.6 million.
Cash, cash equivalents and restricted cash were $5.9 million at Q2 2026, down from $6.3 million at Q1 2026, after a $0.4 million net operating cash burn.
CytoSorbents reported second quarter 2026 results with revenue flat year over year at $9.6 million. Net loss was $4.4 million, or $0.07 per share, compared with net income of $1.9 million, or $0.03 per share, a year earlier; the company attributes the swing mainly to non-cash foreign currency translation changes. Operating loss narrowed 27% to $2.6 million and gross margin rose to 73%, but the balance sheet shows a stockholders' deficit of $0.8 million and $14.1 million of debt classified as current.
Q2 2026 revenue was $9.6 million, unchanged from a year ago; Germany sales fell 24% while distributor and strategic partner sales rose 16%.
Net loss was $4.4 million ($0.07 per share) versus net income of $1.9 million ($0.03 per share) in Q2 2025, mainly due to foreign currency effects.
Operating loss improved to $2.6 million from $3.6 million, and gross margin rose to 73% from 71% a year ago.
Cash, cash equivalents and restricted cash were about $5.9 million at June 30, 2026, versus $6.3 million at March 31, 2026; current debt was $14.1 million.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Cytosorbents Corp filing is on SEC EDGAR ↗. 8-K briefs of other companies →